Developer docs
API playgroundTry for free, no card

Search company profiles

Vaneltix Pharma

Full company profile

uuid002u1vq

Namestring
Vaneltix Pharma
Legal namestring
Vaneltix Pharma, Inc.
Websiteurl
vaneltix.com
Company typeenum
Private
Founded yearstring
-
Descriptiontext

Vaneltix Pharma, Inc. (formerly Urigen Pharmaceuticals, Inc.) is a privately held, pre-commercial specialty pharmaceutical company headquartered in New Brunswick, New Jersey, developing treatments in urology and women's health with a focus on Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS). The company targets an estimated 6+ million US patients suffering from acute pelvic pain, urgency, frequency, and painful flares, an underserved population for whom existing first-line drug therapy is acknowledged as limited.

Its lead asset, Alenura®, is a proprietary combination of heparin and alkalinized lidocaine supplied as a prefilled syringe for intravesicular bladder administration. Alkalinized lidocaine is formulated to penetrate the transitional epithelial cell layer for immediate on-demand pain relief, while heparin augments the bladder's natural glycosaminoglycan (GAG) layer, reducing inflammation and providing anti-microbial properties. Phase 2 trials have shown that the combination produces greater pain relief than either component alone, and the asset is already recognized in AUA and EAU guidelines as a first-line drug therapy option. Vaneltix pursues approval under the FDA 505(b)(2) regulatory pathway for drug repurposing, with a target NDA submission in 2025. The company also holds worldwide IP covering use, composition, and manufacturing, and has a broader pipeline spanning VNX002 (regenerative biologic), VNX003 (improved oral pentosan polysulfate), VNX004 (topical pain), and VNX005 (litoxetine for incontinence, brought in from European Phase 2 for US development).

The business model is pre-commercial and centered on out-licensing and profit-sharing economics rather than direct sales at present. Revenue is contingent on FDA approval of Alenura®; investor materials cite revenue potential above $700 million for Alenura® and peak pipeline sales above $1 billion. A Joint Development Agreement with Hyloris Pharmaceuticals NV (Belgium, December 2021) provides development funding in exchange for a commercialization profit share. Upon approval, the planned go-to-market is enterprise specialty pharma sales targeting urologists first, then OB/GYNs, with products dispensed through standard pharmaceutical distribution channels as prescription-only medications administered in clinical settings. The company has disclosed only $900,000 in equity capital raised (2020 stockholder offering), operates with a simple debt-free capital structure, and employs fewer than 10 people.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersNorth Brunswick, United States
HQ citystring
North Brunswick
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
urology pharmaceuticals, women's health therapeutics, interstitial cystitis treatment, intravesicular drug delivery, bladder pain therapies
Industry2 codes
PRIMARYHLAIACAH
Nephrology & Urology Specialty Pharmaceuticals
SECONDARYHLAIAAAM
Nephrology & Urology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code1 code
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Urology Specialty Pharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Alenura® Commercialization
TypeOne Time License
Description

Vaneltix is a specialty pharmaceutical company in pre-commercial stage, focused on development of therapeutic products. Their lead clinical program Alenura® targets IC/BPS with an estimated revenue potential of over $700M and peak sales estimated at >$1B. The company is pursuing FDA 505(b)(2) regulatory pathway for accelerated approval.

vaneltix.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Vaneltix Pharma is a pre-commercial specialty pharmaceutical company that develops prescription therapeutics for urology and women's health, with lead product Alenura, a heparin and alkalinized lidocaine combination supplied as a prefilled syringe for intravesicular administration to provide on-demand relief of acute pain in Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS). The broader pipeline adds biologic, oral, and topical candidates for bladder epithelium regeneration, oral pentosan polysulfate reformulation, topical pain relief, and stress/mixed incontinence, all pursued under the FDA 505(b)(2) drug repurposing pathway.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Phase 2 trials consistently demonstrate significant separation from placebo in symptoms of pain relief
+4 more records
Product overview1 text field

Vaneltix Pharma is a specialty pharmaceutical company developing a portfolio of treatments for urology and women's health, with its flagship product Alenura® (a heparin and alkalinized lidocaine combination) in late-stage development for acute pain in IC/BPS. The pipeline includes Alenura diagnostic claim, VNX002 Biologic (regenerative therapy for damaged bladder epithelium), VNX003 Oral (improved Elmiron formulation), VNX004 Topical (enhanced pain relief), and VNX005 Oral (incontinence treatment). The company leverages the FDA 505(b)(2) regulatory pathway for drug repurposing.

Product and service6 records
1Alenura®
CategoryLead core product (urology specialty pharma)
Description

Proprietary combination product of heparin and alkalinized lidocaine supplied as a prefilled syringe for intravesicular bladder administration, providing on-demand relief of acute pain episodes associated with Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS).

2Alenura Diagnostic Claim
CategoryPipeline product (urology specialty pharma)
Description

Use of the Alenura heparin/alkalinized lidocaine formulation as a diagnostic tool for fast diagnosis of pelvic pain originating from the bladder.

3VNX002 Biologic
CategoryPipeline product (biologic therapy)
Description

Anabolic biologic therapy intended to stimulate growth of bladder epithelium, for treatment of hemorrhagic cystitis resulting from physical trauma, radiation and chemotherapy for cancer, and severe forms of interstitial cystitis and Hunner's lesions. Currently in pre-clinical stage.

4VNX003 Oral
CategoryPipeline product (oral urology therapy)
Description

Improved oral formulation of pentosan polysulfate (Elmiron) with better absorption and bladder targeting, designed to overcome GI discomfort and reduce systemic exposure by enabling lower doses.

5VNX004 Topical
CategoryPipeline product (topical pain therapy)
Description

Enhanced topical pain relief formulation using alkalinized lidocaine technology adapted from Alenura into novel topical dosage forms for new indications.

6VNX005 Oral
CategoryPipeline product (oral incontinence therapy)
Description

Oral treatment for stress/mixed incontinence using litoxetine, a new oral drug that has completed Phase 2 clinical development and is being developed for US Phase 2b with global Phase 3 preparation.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-12-16
Description

Vaneltix entered into a Joint Development Agreement with Hyloris Pharmaceuticals NV, a Belgian pharmaceuticals company. Under the agreement, Hyloris provides certain funding for the development of Alenura™ product candidate in return for a profit share if and when Alenura™ is commercialized. The partnership is designed to support the development and potential commercialization of Alenura® for treatment of acute pain in Interstitial Cystitis.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Through legacy Pharmacia, Pfizer historically marketed Detrol (tolterodine) for overactive bladder and remains a broad incumbent in urology. As a deep-pocketed potential acquirer, Pfizer is a relevant comparable for specialty urology commercial value.

TypeBroad incumbent
Description

Major urology incumbent with Vesicare (solifenacin) and Myrbetriq (mirabegron) for overactive bladder. Astellas represents the prototypical strategic acquirer of late-stage urology assets and the standard for specialty urology commercial infrastructure.

TypeDirect peer
Description

US clinical-stage specialty pharma developing treatments in immunology and immuno-inflammatory diseases using 505(b)(2) and reformulation approaches. Comparable as a small-cap, clinical-stage specialty pharma pursuing niche indications.

TypeDirect peer
Description

US specialty pharma focused on pain and responsible commercialization of abuse-deterrent formulations, frequently using 505(b)(2) pathways. Comparable in size, regulatory strategy, and commercial focus on a niche pain/urology prescriber base.

TypeBroad incumbent
Description

Markets Botox (onabotulinumtoxinA), which is used off-label in refractory IC/BPS and overactive bladder. As a broad incumbent in urology and pelvic health, AbbVie represents the strategic-acquirer profile for a late-stage IC/BPS asset.

TypeDirect peer
Description

Belgian specialty pharma also focused on the 505(b)(2) repurposing pathway. Hyloris is Vaneltix's joint development partner for Alenura and shares the same hybrid specialty pharma business model, making it the most directly comparable peer.

TypeDirect peer
Description

US specialty pharma focused on niche therapeutic areas using 505(b)(2) and other repurposing strategies. Comparable in size, regulatory approach, and niche-indication commercial model to Vaneltix.

TypeDirect peer
Description

US specialty and generic pharma that builds its portfolio through 505(b)(2) NDAs and niche specialty launches. Comparable in capital structure, repurposing focus, and approach to underserved specialty indications.

TypeBroad incumbent
Description

Markets Elmiron (pentosan polysulfate), the only FDA-approved oral therapy for IC/BPS pain, and VNX003 is essentially an improved version of this drug. As the incumbent in Vaneltix's primary indication, J&J defines the competitive landscape.

TypeEmerging player
Description

Emerging US specialty pharma with a focus on underserved therapeutic areas and 505(b)(2)-style development. Comparable in stage and approach to building a multi-asset specialty franchise.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights8 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Vaneltix Pharma

Urology Specialty Pharmaceuticalsvaneltix.com

What Vaneltix Pharma does

Vaneltix Pharma, Inc. (formerly Urigen Pharmaceuticals, Inc.) is a privately held, pre-commercial specialty pharmaceutical company headquartered in New Brunswick, New Jersey, developing treatments in urology and women's health with a focus on Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS). The company targets an estimated 6+ million US patients suffering from acute pelvic pain, urgency, frequency, and painful flares, an underserved population for whom existing first-line drug therapy is acknowledged as limited.

Its lead asset, Alenura®, is a proprietary combination of heparin and alkalinized lidocaine supplied as a prefilled syringe for intravesicular bladder administration. Alkalinized lidocaine is formulated to penetrate the transitional epithelial cell layer for immediate on-demand pain relief, while heparin augments the bladder's natural glycosaminoglycan (GAG) layer, reducing inflammation and providing anti-microbial properties. Phase 2 trials have shown that the combination produces greater pain relief than either component alone, and the asset is already recognized in AUA and EAU guidelines as a first-line drug therapy option. Vaneltix pursues approval under the FDA 505(b)(2) regulatory pathway for drug repurposing, with a target NDA submission in 2025. The company also holds worldwide IP covering use, composition, and manufacturing, and has a broader pipeline spanning VNX002 (regenerative biologic), VNX003 (improved oral pentosan polysulfate), VNX004 (topical pain), and VNX005 (litoxetine for incontinence, brought in from European Phase 2 for US development).

The business model is pre-commercial and centered on out-licensing and profit-sharing economics rather than direct sales at present. Revenue is contingent on FDA approval of Alenura®; investor materials cite revenue potential above $700 million for Alenura® and peak pipeline sales above $1 billion. A Joint Development Agreement with Hyloris Pharmaceuticals NV (Belgium, December 2021) provides development funding in exchange for a commercialization profit share. Upon approval, the planned go-to-market is enterprise specialty pharma sales targeting urologists first, then OB/GYNs, with products dispensed through standard pharmaceutical distribution channels as prescription-only medications administered in clinical settings. The company has disclosed only $900,000 in equity capital raised (2020 stockholder offering), operates with a simple debt-free capital structure, and employs fewer than 10 people.

Vaneltix Pharma firmographics

Firmographics
Name
Vaneltix Pharma
Legal name
Vaneltix Pharma, Inc.
Website
https://vaneltix.com
Company type
Private
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

Vaneltix Pharma industry classification

Industry
Product category
Urology Specialty Pharmaceuticals
NAICS
Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIACAH
Nephrology & Urology Specialty Pharmaceuticals
SECONDARYHLAIAAAM
Nephrology & Urology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Urology pharmaceuticals
  • Women's health therapeutics
  • Interstitial cystitis treatment
  • Intravesicular drug delivery
  • Bladder pain therapies

Where Vaneltix Pharma is headquartered

Location

Headquarters

HQ city
North Brunswick
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Vaneltix Pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Alenura® Commercialization: Vaneltix is a specialty pharmaceutical company in pre-commercial stage, focused on development of therapeutic products. Their lead clinical program Alenura® targets IC/BPS with an estimated revenue potential of over $700M and peak sales estimated at >$1B. The company is pursuing FDA 505(b)(2) regulatory pathway for accelerated approval.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Vaneltix Pharma product offering

Product offering

Core offering

Vaneltix Pharma is a pre-commercial specialty pharmaceutical company that develops prescription therapeutics for urology and women's health, with lead product Alenura, a heparin and alkalinized lidocaine combination supplied as a prefilled syringe for intravesicular administration to provide on-demand relief of acute pain in Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS). The broader pipeline adds biologic, oral, and topical candidates for bladder epithelium regeneration, oral pentosan polysulfate reformulation, topical pain relief, and stress/mixed incontinence, all pursued under the FDA 505(b)(2) drug repurposing pathway.

Product overview

Vaneltix Pharma is a specialty pharmaceutical company developing a portfolio of treatments for urology and women's health, with its flagship product Alenura® (a heparin and alkalinized lidocaine combination) in late-stage development for acute pain in IC/BPS. The pipeline includes Alenura diagnostic claim, VNX002 Biologic (regenerative therapy for damaged bladder epithelium), VNX003 Oral (improved Elmiron formulation), VNX004 Topical (enhanced pain relief), and VNX005 Oral (incontinence treatment). The company leverages the FDA 505(b)(2) regulatory pathway for drug repurposing.

Differentiator

Problem solved

Functional benefit

Products and services

  • Alenura® Proprietary combination product of heparin and alkalinized lidocaine supplied as a prefilled syringe for intravesicular bladder administration, providing on-demand relief of acute pain episodes associated with Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS).
  • Alenura Diagnostic Claim Use of the Alenura heparin/alkalinized lidocaine formulation as a diagnostic tool for fast diagnosis of pelvic pain originating from the bladder.
  • VNX002 Biologic Anabolic biologic therapy intended to stimulate growth of bladder epithelium, for treatment of hemorrhagic cystitis resulting from physical trauma, radiation and chemotherapy for cancer, and severe forms of interstitial cystitis and Hunner's lesions. Currently in pre-clinical stage.
  • VNX003 Oral Improved oral formulation of pentosan polysulfate (Elmiron) with better absorption and bladder targeting, designed to overcome GI discomfort and reduce systemic exposure by enabling lower doses.
  • VNX004 Topical Enhanced topical pain relief formulation using alkalinized lidocaine technology adapted from Alenura into novel topical dosage forms for new indications.
  • VNX005 Oral Oral treatment for stress/mixed incontinence using litoxetine, a new oral drug that has completed Phase 2 clinical development and is being developed for US Phase 2b with global Phase 3 preparation.

Quantifiable outcome

  • Phase 2 trials consistently demonstrate significant separation from placebo in symptoms of pain relief
  • +4 more outcomes

Companies that use Vaneltix Pharma

Customer profile

Segments3 records

Ideal customer profiles2 records

Vaneltix Pharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Vaneltix Pharma partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Hyloris Pharmaceuticals NVcoreStrategic or Co-development Partner · 16 December 2021Vaneltix entered into a Joint Development Agreement with Hyloris Pharmaceuticals NV, a Belgian pharmaceuticals company. Under the agreement, Hyloris provides certain funding for the development of Alenura™ product candidate in return for a profit share if and when Alenura™ is commercialized. The partnership is designed to support the development and potential commercialization of Alenura® for treatment of acute pain in Interstitial Cystitis.

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Vaneltix Pharma competitors and assessment

Company assessment

Broad incumbents

  • Pfizer: Through legacy Pharmacia, Pfizer historically marketed Detrol (tolterodine) for overactive bladder and remains a broad incumbent in urology. As a deep-pocketed potential acquirer, Pfizer is a relevant comparable for specialty urology commercial value.
  • Astellas Pharma: Major urology incumbent with Vesicare (solifenacin) and Myrbetriq (mirabegron) for overactive bladder. Astellas represents the prototypical strategic acquirer of late-stage urology assets and the standard for specialty urology commercial infrastructure.
  • AbbVie (Allergan): Markets Botox (onabotulinumtoxinA), which is used off-label in refractory IC/BPS and overactive bladder. As a broad incumbent in urology and pelvic health, AbbVie represents the strategic-acquirer profile for a late-stage IC/BPS asset.
  • Johnson & Johnson (Janssen): Markets Elmiron (pentosan polysulfate), the only FDA-approved oral therapy for IC/BPS pain, and VNX003 is essentially an improved version of this drug. As the incumbent in Vaneltix's primary indication, J&J defines the competitive landscape.

Direct peers

  • Aclaris Therapeutics: US clinical-stage specialty pharma developing treatments in immunology and immuno-inflammatory diseases using 505(b)(2) and reformulation approaches. Comparable as a small-cap, clinical-stage specialty pharma pursuing niche indications.
  • Collegium Pharmaceutical: US specialty pharma focused on pain and responsible commercialization of abuse-deterrent formulations, frequently using 505(b)(2) pathways. Comparable in size, regulatory strategy, and commercial focus on a niche pain/urology prescriber base.
  • Hyloris Pharmaceuticals: Belgian specialty pharma also focused on the 505(b)(2) repurposing pathway. Hyloris is Vaneltix's joint development partner for Alenura and shares the same hybrid specialty pharma business model, making it the most directly comparable peer.
  • Harrow Health: US specialty pharma focused on niche therapeutic areas using 505(b)(2) and other repurposing strategies. Comparable in size, regulatory approach, and niche-indication commercial model to Vaneltix.
  • ANI Pharmaceuticals: US specialty and generic pharma that builds its portfolio through 505(b)(2) NDAs and niche specialty launches. Comparable in capital structure, repurposing focus, and approach to underserved specialty indications.

Emerging players

  • Tarsus Pharmaceuticals: Emerging US specialty pharma with a focus on underserved therapeutic areas and 505(b)(2)-style development. Comparable in stage and approach to building a multi-asset specialty franchise.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights8 records

Customer concentration

Vaneltix Pharma social profiles

Digital presence

Vaneltix Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Vaneltix Pharma leadership team

Management profile

Number of profiles

Profiles7 records

Vaneltix Pharma funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Vaneltix Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vaneltix Pharma

What does Vaneltix Pharma do?

Vaneltix Pharma is a pre-commercial specialty pharmaceutical company that develops prescription therapeutics for urology and women's health, with lead product Alenura, a heparin and alkalinized lidocaine combination supplied as a prefilled syringe for intravesicular administration to provide on-demand relief of acute pain in Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS). The broader pipeline adds biologic, oral, and topical candidates for bladder epithelium regeneration, oral pentosan polysulfate reformulation, topical pain relief, and stress/mixed incontinence, all pursued under the FDA 505(b)(2) drug repurposing pathway.

Is Vaneltix Pharma a public or private company?

Vaneltix Pharma is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Vaneltix Pharma founded?

Vaneltix Pharma was founded in -1. It employs 11 to 50 people.

Where is Vaneltix Pharma based?

Vaneltix Pharma is headquartered in North Brunswick, United States, in the North America region.

How does Vaneltix Pharma make money?

One revenue line is on record: alenura® Commercialization.

Who are Vaneltix Pharma's main competitors?

Broad incumbents on record are Pfizer, Astellas Pharma, AbbVie (Allergan) and Johnson & Johnson (Janssen). Direct peers are Aclaris Therapeutics, Collegium Pharmaceutical, Hyloris Pharmaceuticals, Harrow Health and ANI Pharmaceuticals. Tarsus Pharmaceuticals is listed as an emerging player.

Does Vaneltix Pharma have an API?

No public API is recorded for Vaneltix Pharma.

What industry is Vaneltix Pharma in?

Vaneltix Pharma's product category is Urology Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAIACAH, Nephrology & Urology Specialty Pharmaceuticals, with a secondary code of HLAIAAAM, Nephrology & Urology Pharmaceuticals. Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals